



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Eflapegrastim

<b>Cat. No.:</b>	HY-P99913
<b>CAS No.:</b>	1384099-30-2
<b>Target:</b>	c-Fms
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Eflapegrastim is a human IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia <sup>[1]</sup> .	
<b>In Vitro</b>	Eflapegrastim has an IgG4 Fc fragment and short polyethylene glycol linker <sup>[1]</sup> . Eflapegrastim (5.5-88 mM; 4 min) binds to FcRn but not Fcγ receptors or C1q <sup>[1]</sup> . Eflapegrastim (0.000036-0.709 nmol/L; 54 h) induces bone marrow cell proliferation <sup>[1]</sup> . Eflapegrastim (10 μM; 1 h) binds FcRn and undergoes FcRn-mediated transcytosis <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
<b>In Vivo</b>	Eflapegrastim (100 μg/kg; s.c.; single dose) decreases the duration of neutropenia (DN) and increases levels of G-CSF in serum and marrow in chemotherapy-induced neutropenic rats <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	<b>Animal Model:</b>	C57BL/6NCrI mice (4-6 weeks old) <sup>[1]</sup>
	<b>Dosage:</b>	(1) 9, 26, 53, and 88 μg/kg; (2) 62 μg/kg
	<b>Administration:</b>	Subcutaneous injection; single dose
	<b>Result:</b>	Reduced chemotherapy-induced neutropenia.

### REFERENCES

[1]. Barrett JA, et al. Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing. *Exp Hematol*. 2020 Dec;92:51-61.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA